Cerluten vs Vilon

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Khavinson-class bioregulators are typically formulated as oral capsules and studied in intermittent cycles consistent with the gene-regulatory mechanism proposed for this peptide class; no validated human dosing regimen exists for cerluten in any jurisdiction. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Synthetic dipeptide Lys-Glu; modulates T-cell and NK cell activity; reduces age-related immune decline; normalizes cytokine production via epigenetic gene regulation

Vilon is a synthetic dipeptide (Lys-Glu, KE) classified as a Khavinson-class bioregulator originally derived from thymic tissue, proposed to modulate immune function in aging subjects by providing minimal thymic regulatory dipeptide signals that support T-lymphocyte activation and immune homeostasis diminished by age-related thymic involution. As the minimal active dipeptide unit of the Khavinson thymic bioregulator class, vilon is proposed to act through amino acid transporter uptake and modulation of intracellular signaling — including sphingomyelin pathway signal transduction in thymocytes — to restore T-cell activation thresholds and proliferative responses in immune cells from elderly subjects. Research has characterized natural and synthetic thymic peptides including vilon as therapeutic candidates for immune dysfunction, and experimental work has demonstrated that short Khavinson-class peptides modulate thymocyte blast transformation and sphingomyelin pathway signaling in immune cell preparations. Vilon has no FDA approval; evidence derives from Khavinson-series Russian preclinical and observational studies, and it has no regulatory approval in any major Western jurisdiction.